Charles Schwab Investment Management Inc Cytom X Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 24,817 shares of CTMX stock, worth $26,306. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,817

Previous 24,817 -0.0%

Holding current value

$26,306

Previous $30,000 3.33%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.48 - $2.88 $25,757 - $50,123	-17,404 Reduced 41.22%	24,817 $37,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $51,931 - $83,175	42,221 New	42,221 $62,000
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $255,782 - $483,144	-167,178 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $8,447 - $14,807	3,164 Added 1.93%	167,178 $447,000
Q4 2021 Feb 11, 2022	SELL	$3.87 - $7.39 $944 - $1,803	-244 Reduced 0.15%	164,014 $711,000
Q3 2021 Nov 16, 2021	SELL	$4.32 - $6.43 $1.49 Million - $2.22 Million	-345,671 Reduced 67.79%	164,258 $837,000
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $103,938 - $162,722	16,420 Added 3.33%	509,929 $3.23 Million
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $916,515 - $1.25 Million	138,866 Added 39.16%	493,509 $3.82 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $203,164 - $248,067	31,401 Added 9.71%	354,643 $2.32 Million
Q3 2020 Nov 13, 2020	SELL	$6.55 - $8.83 $27,261 - $36,750	-4,162 Reduced 1.27%	323,242 $2.15 Million
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $326,199 - $645,345	44,081 Added 15.56%	327,404 $2.73 Million
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $100,516 - $239,458	27,844 Added 10.9%	283,323 $2.17 Million
Q4 2019 Feb 07, 2020	SELL	$5.17 - $8.91 $88,422 - $152,387	-17,103 Reduced 6.27%	255,479 $2.12 Million
Q3 2019 Nov 08, 2019	BUY	$7.38 - $12.25 $62,811 - $104,259	8,511 Added 3.22%	272,582 $2.01 Million
Q2 2019 Aug 09, 2019	SELL	$9.35 - $11.41 $357,431 - $436,181	-38,228 Reduced 12.65%	264,071 $2.96 Million
Q1 2019 May 14, 2019	BUY	$9.5 - $19.16 $50,673 - $102,199	5,334 Added 1.8%	302,299 $3.25 Million
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $196,111 - $287,598	-15,454 Reduced 4.95%	296,965 $4.49 Million
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $1.38 Million - $2.02 Million	76,493 Added 32.42%	312,419 $5.78 Million
Q2 2018 Aug 08, 2018	BUY	$21.38 - $29.68 $803,032 - $1.11 Million	37,560 Added 18.93%	235,926 $5.39 Million
Q1 2018 May 07, 2018	BUY	$21.76 - $34.22 $475,760 - $748,186	21,864 Added 12.39%	198,366 $5.64 Million
Q4 2017 Jan 17, 2018	BUY	$19.0 - $23.09 $157,301 - $191,162	8,279 Added 4.92%	176,502 $3.73 Million
Q3 2017 Nov 13, 2017	BUY	$13.53 - $18.17 $2.28 Million - $3.06 Million	168,223	168,223 $3.06 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Cytom X Therapeutics, Inc. Transaction History